TY - JOUR
T1 - In vitro testing for hypersensitivity-mediated adverse drug reactions
T2 - Challenges and future directions
AU - Elzagallaai, A. A.
AU - Koren, G.
AU - Bend, J. R.
AU - Rieder, M. J.
PY - 2011/9
Y1 - 2011/9
N2 - Drug hypersensitivity reactions (DHRs) are uncommon but potentially fatal adverse events. Their diagnosis and prediction are difficult given their variable presentation and the overlap of symptoms with those of other clinical conditions. Systemic rechallenge is considered the gold standard for the diagnosis of DHRs; however, this may have severe consequences. In vitro tests are currently not sufficiently reliable to provide the basis for clinical decisions. This article summarizes the challenges associated with in vitro testing for DHRs.
AB - Drug hypersensitivity reactions (DHRs) are uncommon but potentially fatal adverse events. Their diagnosis and prediction are difficult given their variable presentation and the overlap of symptoms with those of other clinical conditions. Systemic rechallenge is considered the gold standard for the diagnosis of DHRs; however, this may have severe consequences. In vitro tests are currently not sufficiently reliable to provide the basis for clinical decisions. This article summarizes the challenges associated with in vitro testing for DHRs.
UR - http://www.scopus.com/inward/record.url?scp=80052024836&partnerID=8YFLogxK
U2 - 10.1038/clpt.2011.155
DO - 10.1038/clpt.2011.155
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 21814194
AN - SCOPUS:80052024836
SN - 0009-9236
VL - 90
SP - 455
EP - 460
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 3
ER -